Background. Identification of fungi causing invasive fungal disease (IFD) is critical for guiding antifungal therapy. We describe the performance and clinical impact of a targeted panfungal polymerase chain reaction (PCR) amplicon sequencing assay for culture-independent diagnosis of IFD.
Over the recent decades, the incidence of invasive fungal disease (IFD) has significantly increased in parallel with expansion of immunocompromised populations [1] [2] [3] . IFD is associated with higher morbidity and mortality, and increased healthcare costs [1] [2] [3] [4] [5] . Delay in diagnosis and institution of appropriate antifungal therapy is strongly associated with poor outcomes [6, 7] . However, diagnosing IFD remains challenging due to a number of factors. First, clinical and radiographic manifestations of IFD are nonspecific. Second, preanalytical factors such as empiric antifungal therapy and sample processing (ie, tissue homogenization) can adversely affect the yield of fungal culture [8] [9] [10] . Third, conventional laboratory methods such as microscopy and culture lack sensitivity; culture sensitivity ranges from 30% to 60% [8, 11] . Further, histopathology and cytology are unable to accurately identify fungi to genus or species level compared with culture, with reported discordance rates of up to 20% [12] [13] [14] . Last, fungal biomarkers such as serum β-d-glucan or Aspergillus galactomannan, although attractive due to their noninvasive nature, are unable to confirm or exclude IFD in most clinical scenarios [15, 16] . Therefore, culture-independent assays that provide accurate and timely identification of all invasive fungi are urgently needed to guide clinical practice.
Nucleic acid amplification tests (NAATs) have emerged in the past decade as the culture-independent methods of choice for a number of infectious diseases [17, 18] . Targeted panfungal polymerase chain reaction (PCR) amplicon sequencing (herein referred to as fungal sequencing) allows rapid detection and identification of fungi in clinical specimens [19] [20] [21] . Fungal sequencing assays target one or more regions in the multicopy ribosomal RNA (rRNA) genomic locus, such as the 18S rRNA, D1 and D2 regions of 28S rRNA, 5.8S rRNA, and internal transcribed spacers 1 and 2 (ITS1 and ITS2) [17, 21] . Although targeted fungal sequencing has been available for clinical testing, there is a paucity of studies describing its performance under routine clinical practice.
In this study, we investigated the diagnostic accuracy and clinical impact of a laboratory-developed targeted fungal sequencing assay in patients with known and suspected diagnosis of IFD.
MATERIALS AND METHODS

Ethics
This study was approved by the Stanford University Institutional Review Board.
Study Design
We retrospectively evaluated the performance of targeted fungal sequencing for diagnosis of IFD in patients with known and suspected diagnosis of IFD. Specimens with positive reference method results (n = 60) were used to evaluate assay sensitivity. Specimens with negative culture results (n = 57) and no ancillary evidence of IFD, including absence of fungal elements in tissue sections and body fluids, were used to evaluate assay specificity. Specimens with negative culture results but with microscopic and other ancillary evidence of IFD (n = 116) (Supplementary Table 6 ), including 107 fresh and formalin-fixed, paraffin-embedded (FFPE) tissues and 9 sterile body fluids, were used to evaluate the diagnostic yield of fungal sequencing in patients with suspected IFD.
Clinical Specimens
Between January 2009 and September 2016, clinical specimens sent to Stanford Health Care Clinical Microbiology laboratory for fungal sequencing were included in this study. Samples were categorized as fresh tissue, FFPE tissue, and sterile body fluid. Fresh tissue was chosen over FFPE for fungal sequencing when concurrent samples were available. Although not considered sterile body fluid, 3 bronchoalveolar lavage (BAL) samples positive by culture for Coccidioides immitis/posadasii, Candida glabrata, and C. albicans were included for sensitivity analysis. See Supplementary Table 6 for specimens used to evaluate diagnostic yield in patients with suspected IFD.
Medical Records Review
Electronic medical records were reviewed to extract clinical data and laboratory findings to classify patients' IFD diagnosis according to the European Organization for Research and Treatment of Cancer/ Mycoses Study Group (EORTC/ MSG) [15] . In patients with suspected IFD and positive fungal sequencing results, impact of pathogen identification on patient management (ie, antifungal therapy and surgical intervention) was determined. Cases from outside institutions (n = 20), for which medical records were not available, and autopsy cases (n=5) were excluded. We also classified biopsy type as open resection, core-needle biopsy, and fine needle aspiration (FNA). Tissue sampling through transbronchial needle puncture or transjugular liver biopsy were considered core-needle biopsies.
Fungal Stain and Culture
Calcofluor-white stain with 10% potassium hydroxide was performed on tissue homogenates and sterile body fluids. Tissue biopsies obtained via open resection were minced for culture. Specimens were inoculated into potato flake agar and CHROMagar Candida (Becton Dickinson, Sparks, Maryland) and incubated at 30°C and 35°C, respectively. Cultures were assessed for growth daily for the first 5 days and then biweekly for up to 21 days. Positive cultures were identified using various methods including macroscopic and microscopic examination, VITEK 2 ID card (bioMérieux, Durham, North Carolina), matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF) (Bruker Daltonics, Billerica, Massachusetts), and targeted fungal sequencing.
Fungal Sequencing
Was performed as previously described [19] . For details, see Supplementary Materials. In brief, DNA was extracted from fresh tissues and fluids using QIAamp DNA Mini Kit (Qiagen, Valencia, California) and from FFPE tissues using EZ1 DNA Tissue Kit (Qiagen). Real-time PCR was performed using panfungal primers for ITS2 and D2, and primers targeting the human β-actin gene. The latter was performed as an internal control for DNA extraction and to assess for PCR inhibition, which was defined as flat amplification curve with no melting peak or decrease in the slope of the amplification curve relative to the positive control. When PCR inhibition was present and ITS2 and D2 failed to amplify, the DNA extract was diluted 1:10 and PCR was repeated. Samples with unresolved inhibition were reported as indeterminate. Amplicons were sequenced using cycle sequencing. Sequences were identified using the National Center for Biotechnology Information's GenBank (http://www. ncbi.nlm.nih.gov/Genbank/) and Westerdijk Fungal Biodiversity Centre (http://www.westerdijkinstitute.nl/). Resolution to species and genus level was made with percentage identity score of ≥99.0% and ≥98.0% to <99.0%, respectively. For Aspergillus and Trichophyton, assignment to species level and species complex level was determined with percentage identity score of ≥99.5% and ≥99.0% to <99.5%, respectively [22] . Matching results for ITS2 and D2 were required. If discordant or only one target provided sequence result, extraction and sequencing were repeated. Upon repeat, if result remained unchanged, clinical correlation was performed before reporting a fungal identification result.
Slide Review
Histopathology slides stained with Grocott methenamine silver and/or periodic acid-Schiff from cases of suspected IFD with negative fungal sequencing but positive histopathology results were reviewed by 2 investigators with pathology training (A. J. Z. and N. B.) to confirm the presence of fungal elements reported by the attending pathologist signing out the case. For fresh tissues with negative fungal sequencing results, histopathology slides from concurrent FFPE tissues were reviewed. In 9 of 40 discordant cases, slides were not available for review.
Statistical Analysis
Sensitivity and specificity were calculated. Proportional outcomes were compared using χ 2 test or Fisher exact test. Continuous variables were compared using the Student t test or Wilcoxon signed-rank test. All tests for significance were 2 sided, and P values ≤.05 were considered significant. Statistical analyses were performed using Prism 7.0 software (GraphPad, La Jolla, California).
RESULTS
Accuracy of Targeted Fungal Sequencing in Patients With Known Diagnosis of Invasive Fungal Disease
The sensitivity and specificity of fungal sequencing were 96.6% (95% confidence interval [CI], 87.4%-99.4%; 58/60) and 98.2% (95% CI, 89.4%-99.9%; 56/57), respectively ( Table 1 ). The specimen types, reference method results, and fungal species identified by sequencing are shown in Table 1 Clinical characteristics of 108 patients with suspected IFD are shown in Table 2 . Specimen types tested are described in Supplementary Tables 4-6 . Overall, fungal sequencing identified a fungal pathogen in 62.9% (73/116) of specimens (Table 3) . Fungal sequencing did not detect any mixed infections. Fungal sequencing identified a fungal pathogen in 71.3% (57/80) of patients classified with proven IFD per the EORTC/MSG criteria compared with 17.6% (3/17) of patients who did not meet the EORTC/ MSG criteria for IFD (Table 3 ). The fungal species identified are shown in Figure 1 . Aspergillus species (n = 22), Mucorales agents (n = 17), Candida species (n = 11), and dimorphic fungi (n = 7) represented the most common fungi identified by sequencing. (Figure 2) .
The ITS-2 and D2 sequence results were concordant in 78.1% (57/73) of cases. In 16.4% (12/73) of cases, only the D2 allowed fungal identification, 66.7% (8/12) of which were Mucorales agents. In 5.5% (4/73) of cases, only the ITS-2 allowed fungal identification, 75.0% (3/4) of which were yeast.
Review of histopathology slides in cases with fungal elements but negative fungal sequencing results confirmed the presence of fungal elements in all 31 cases with slides available for review. Histopathological findings reported in the pathology report, such as necrosis, type of inflammation, and fungal angioinvasion did not correlate with negative fungal sequencing results (data not shown). However, expected fungal morphologies (ie, hyphae, yeast, and spherules) based on agents identified by fungal sequencing agreed 100% (52/52) with observed fungal morphologies based on histopathology and Calcofluor-white staining (Table 4) .
Diagnosis of Invasive Protozoal Infections
The D2 primers employed in this fungal sequencing assay cross-react in silico with several medically important protozoa that cause invasive disease. Thus, this assay should also provide partial-protozoal coverage in cases of certain invasive protozoal infections. During the course of this study, D2 amplicon sequencing identified Toxoplasma gondii in brain tissues of 3 immunocompromised patients with encephalitis; Trypanosoma cruzi in brain tissue of a human immunodeficiency virus/AIDS-infected Salvadoran patient with encephalitis; and Leishmania species in skin biopsy of a returned traveler from Ecuador with cutaneous ulcers. The D2 sequencing results for the 3 toxoplasmosis cases and one leishmaniasis case were confirmed with immunostaining and/or pathogen-specific PCR.
Impact of Fungal Sequencing on Patient Management
Medical records were available for 48 of 73 patients with suspected IFD to determine the impact of fungal sequencing results on patient management. In 54% (26/48), fungal sequencing result triggered modification of empiric antifungal therapy with a median time to modification of 2 days (range, 1-42 days) and in 4.2% (2/48) it triggered surgical lung resection within 2 days in patients with localized pulmonary mucormycosis. Fungal sequencing result did not trigger modification of empiric antifungal therapy in 46% (22/48) of patients; 82% (18/22) had adequate antifungal coverage and 18% (4/22) were transitioned to comfort care or died prior to availability of fungal sequencing results. In patients with antifungal modification, 50% (13/26) had their antifungal therapy tailored to the species identified by sequencing (most commonly intravenous amphotericin B changed to oral voriconazole), 35% (9/26) had a new antifungal agent added to empiric regimen (combination therapy), and 15% (4/26) were started on appropriated antifungal therapy. For the 5 cases of invasive protozoal infection, sequencing results led to initiation of appropriate antiparasitic therapy. In the 3 cases of toxoplasma encephalitis, sequencing result triggered initiation of antitoxoplasma agents and discontinuation of antibacterials and antifungals intended for other opportunistic pathogens. In the case of cutaneous leishmaniasis and chagasic encephalitis, sequencing results prompted initiation of appropriate antiprotozoal therapies.
DISCUSSION
Accurate identification of fungi causing invasive mycosis is pivotal for guiding optimal antifungal therapy and timely de-escalation of therapy. In this study, we demonstrated that fungal sequencing targeting the ribosomal ITS2 and D2 regions is highly sensitive and specific for identification of fungi in patients with known diagnosis of IFD. In this cohort, fungal sequencing had sensitivity of 96.6% and specificity of 98.2% in tissues (fresh and FFPE) and sterile body fluids obtained from diverse sources. In contrast, 44.4% of the aspergillosis and 66.7% candidiasis cases diagnosed with fungal sequencing had a positive galactomannan and β-d-glucan, respectively. Although commonly used in clinical practice, these biomarkers have poor accuracy in immunocompromised populations [23, 24] . We also demonstrated the clinical utility of targeted fungal sequencing in patients with highly suspected IFD but with negative fungal culture results. In this group, fungal sequencing had a diagnostic yield of 71.3% in patients classified as proven IFD per the EORTC/MSG criteria. Importantly, the yield of fungal sequencing was significantly higher in specimens collected by open resection compared with core-needle biopsy and fine-needle aspiration. This finding indicates that the diagnostic yield of fungal sequencing depends heavily on the biopsy method and therefore the amount of tissue available for fungal sequencing. Clinical specimens collected by open biopsy yield considerable amount of tissue. Even after using a portion for histopathology and fungal culture, a sizeable amount still remains for fungal sequencing. In contrast, specimens acquired through core-needle biopsy, FNA, and other percutaneous approaches are scant to start with and little remains for additional testing. A method that objectively evaluates sample volume adequacy for fungal sequencing would be useful. PCR cycle threshold for a human gene target such as β-actin, used as internal control for DNA extraction, may be a useful surrogate for tissue sufficiency if cycle threshold can be correlated with input tissue volume. Altogether, our findings underscore the need for a proactive approach to secure a portion of specimens from high-risk patients for fungal sequencing, especially when limited amount of tissue is obtained through a minimally invasive method.
A handful of studies that have investigated the sensitivity of targeted panfungal sequencing assays on tissue specimens, using fungal culture as a comparator, reported sensitivities >90% [20, 25] . In contrast, the reported diagnostic yield of targeted fungal sequencing performed on clinical specimens with culture-negative/histopathology-positive results varied from 35% to 70% [20, [25] [26] [27] [28] [29] [30] . The sensitivity and diagnostic yield of the fungal sequencing assay used in this study are among the highest reported in the literature [20, [25] [26] [27] [28] . Prior studies differed in their molecular targets, PCR format (conventional vs real-time), DNA extraction method, definition of IFD (eg, based on EORTC/MSG criteria), and clinical specimens tested (sterile vs nonsterile tissues/fluids). At our institution, we restrict testing to patient specimens with visible fungal elements on histopathology, thus increasing the pretest probability of getting a positive sequencing result. This may have contributed to a higher diagnostic yield in this study. Studies describing the use of fungal NAATs on specimens without fungal elements have reported marginal diagnostic yields (<10%) and raised concerns about false-positive results, especially when nonsterile samples (eg, BAL) were tested [28, 31] . In our experience, in the absence of ancillary results in support of IFD (ie, fungal biomarkers such as galactomannan and β-d-glucan), the yield of fungal sequencing is extremely low when fungal elements are not observed on histopathology. In contrast, fungal sequencing did identify fungi in sterile body fluids with negative Calcofluorwhite stain in patients with concurrent IFD in a different anatomical site. Although a false-positive sequencing result is still possible in suspected cases with visible fungal elements, we showed that fungal morphologies observed on histopathology and Calcofluor-white stain always matched their expected morphology based on sequence identification result. Last, given the partial-protozoal coverage offered by the D2 primers, this assay allows a broader approach in clinical instances when both fungal and opportunistic protozoal (eg, T. gondii, Leishmania species, and T. cruzi) agents are included in the differential diagnosis.
Although fungal sequencing is tremendously beneficial for management of patients with IFD, it is important to recognize the potential for false results as a consequence of inadvertent errors during preanalytical and analytical steps. During sample procurement, contamination with commensal and environmental fungi can result in a false-positive result. Maintenance of a well-structured laboratory workflow is crucial to prevent fungal amplicon contamination, which is one of the greatest challenges in molecular diagnostic laboratories using open platforms [17] . Testing samples from nonsterile sources should be avoided and fungal PCR sequencing results must always be correlated with clinical and histopathology findings. Upon identification of unusual or less common fungi, the entire assay should be repeated from a new DNA extract to ensure reproducibility. The accuracy of pathogen identification by sequencing is also contingent on having access to a sequence database that contains accurate and complete sampling of fungal taxonomy. Public databases such as GenBank may contain erroneous entries, or incomplete taxon sampling of fungi causing disease, leading to misidentification of rare fungi [32] . Last, ITS2 and D2 do not allow species-level identification for all fungi. Thus, accurate identification of certain fungi requires sequence analysis of alternative genes [22] .
Despite promising findings, this study has several limitations. First, the study was conducted at a single academic center. The diagnostic yield of our fungal sequencing assay might be different at institutions with different patient populations and medical practices. Second, we did not evaluate the turnaround time of targeted fungal sequencing, which can vary from 1 to 7 days depending on the batching practices and resources available [21, 32] . Combining fungal sequencing with species-specific NAATs with shorter turnaround time may identify a multistep algorithm with simpler workflow and more rapid turnaround time [30, 33] . Third, although we demonstrated that pathogen identification by fungal sequencing has an impact on antifungal therapy and surgical intervention in the majority of cases, we did not measure the impact of fungal sequencing on patient outcomes. Future studies should focus on the impact of fungal sequencing on patient-centered outcomes (ie, length of stay and mortality), antifungal stewardship, and cost-savings. Last, we did not compare targeted sequencing to metagenomics next-generation sequencing for diagnosis of IFD [34] . Studies are needed to compare the accuracy, turn-around-time, and cost of metagenomics NGS to targeted sequencing.
In conclusion, targeted fungal sequencing accurately identified pathogenic fungi in tissues and body fluids from patients with known and suspected IFD. Fungal sequencing guided patient management in the latter group. However, the diagnostic yield of fungal sequencing was dependent on the biopsy method and, thus, the amount of tissue available for testing.
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